Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373789 | 1.00 | P2RX7 (0.42) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL3377080 | 1.00 | P2RX7 (0.42) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL3377787 | 1.00 | P2RX7 (0.42) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL7832081 | 0.98 | P2RX7 (0.41) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL3377077 | 0.98 | P2RX7 (0.40) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL3375323 | 0.95 | P2RX7 (0.38) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL15295683 | 0.92 | CTSK (0.39) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL7279905 | 0.85 | P2RX7 (0.40) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL3372646 | 0.85 | CTSK (0.35) | P2RX7EPHX1CTSKGAACTSL | |
| SCHEMBL3398195 | 0.83 | HPGD (0.39) | EPHX1MEN1KMT2APPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2999711-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3351540-B1 | CYCLOHEXANE DERIVATIVE OR STEREOISOMER OR SALT THEREOF, AND PREPARATION AND USE THEREOF | ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2019-09-10 | — | — | US | disclosed |
| US-10301277-B2 | Substituted ureas and methods of treating mental illness using the same | ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180297975-A1 | CYCLOHEXANE DERIVATIVE OR STEREOISOMER OR SALT THEREOF, AND PREPARATION AND USE THEREOF | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2018-10-18 | — | — | US | disclosed |
| EP-3351540-A1 | CYCLOHEXANE DERIVATIVE OR STEREOISOMER OR SALT THEREOF, AND PREPARATION AND USE THEREOF | Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) | 2018-07-25 | — | — | EP | disclosed |
| CN-106518841-A | Cyclohexane derivative or stereoisomer or salt and preparation and application thereof | 浙江京新药业股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-20160222061-A1 | Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2016-08-04 | — | — | US | disclosed |
| EP-1663996-B1 | (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2012-06-20 | — | — | EP | disclosed |
| EP-1438302-B1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2012-05-30 | — | — | EP | disclosed |
| US-6521638-B1 | Such as 2-(2-(1-(4-(3-(3-methanesulfonyl)phenylpropenoyl)-amino)cyclohexyl)ethyl) -2,3-dihydro-1H-isoindole; amidation of amine and carbonyl halide | SMITHKLINE BEECHAM P.L.C. (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-1086095-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2002-10-23 | — | — | EP | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| US-6414154-B1 | TREATING PSYCHOTIC CONDITIONS OR SUBSTANCE ABUSE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-02 | — | — | US | disclosed |
| US-6358974-B1 | USED AS AS MODULATORS OF DOPAMINE D.SUB.3 RECEPTORS, IN THERAPY AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-19 | — | — | US | disclosed |
| CN-1329609-A | Tetrahydrobenza epine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2002-01-02 | — | — | CN | disclosed |
| EP-1137638-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-10-04 | — | — | EP | disclosed |
| EP-1119563-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000024717-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000021951-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222061-A1 | Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics | MRPS18A, MRPL21, RRP1B | P2RX7 331/4885EPHX1 3840/4885CTSK 1984/4885 |
| US-20180297975-A1 | CYCLOHEXANE DERIVATIVE OR STEREOISOMER OR SALT THEREOF, AND PREPARATION AND USE THEREOF | DRD2, DRD3, HTR3D | P2RX7 1975/4885EPHX1 1901/4885CTSK 3167/4885 |
| US-10301277-B2 | Substituted ureas and methods of treating mental illness using the same | CRHR1, UTS2R, HTR2C | P2RX7 1097/4885EPHX1 3583/4885CTSK 3136/4885 |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | MRPS18A, MRPL21, RRP1B | P2RX7 331/4885EPHX1 3840/4885CTSK 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.